WELCOME TO The Biotechnology REPORT
Santa Cruz Biotechnology (SCBT)
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Fauna | June 15, 2022
Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map. With Centaur, Fauna Bio is able to more rapidly identify human disease indications and targets to generate new therapeutic solutions for some of the mo...
Celyad Oncology | August 01, 2022
Celyad Oncology SA a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the CYAD-101-002 Phase 1b trial after the Company made changes to the eligibility criteria for the trial.
“We are pleased that the FDA lifted the clinical hold on this trial. We remain confident in the p...
Angstrom Bio | October 14, 2020
Angstrom Bio, Inc. today announces the launch of AMPD™, its nanopore sequencing and machine learning powered platform for high-accuracy, high-frequency, low-cost COVID-19 and respiratory pathogen testing. AMPD leverages the extreme resolution and bandwidth of nanopore sequencing to provide the accuracy and volume necessary to detect the earliest stages of exposure to pathogens like SARS-CoV-2 and influenza and to enable schools and places of work to reopen safely and confidently. Angstrom ...
BioSpace | February 17, 2020
Neuropore Therapies, Inc., a biopharmaceutical company discovering and developing novel therapeutics for the treatment of neurodegenerative disorders, announced today that it has been awarded a $500,000 grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis. The grant has been made through the Association’s Lawrence and Isabel Barnett Drug Devel...
CELL AND GENE THERAPY
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE